EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Impact of Desloratadine on Treatment Response and Inflammation During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: A Randomized Pilot Study

Hossein Azimi, Afifeh Jafari, Seyed Reza Khandozi, Yasser Bagheri, Marie Saghaeian Jazi, Somayeh Ghorbani, Gholamreza Roshandel, Homa Davoodi

Archives of Medical Research · 2026

DOI: 10.1016/j.arcmed.2025.103333 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Archives of Medical Research, 2026. Verfasst von Hossein Azimi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. Hauptthemen laut MEDLINE: Loratadine, Breast Neoplasms, Neoadjuvant Therapy, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Golestan University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Desloratadine, commonly used for allergy symptoms, has demonstrated its potential to increase survival rates in patients with breast cancer. This trial aimed to assess the efficacy of desloratadine in improving treatment response and inflammation markers during neoadjuvant chemotherapy. METHODS: In this single-blind, pilot phase II trial, 49 patients with newly diagnosed breast cancer were randomized into two groups: an intervention group (n = 23), and a control group (n = 26). The intervention group received desloratadine in addition to anthracycline-based chemotherapy, while the control group received standard anthracycline-based chemotherapy alone. The primary endpoint was the treatment response, which was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST). Secondary endpoints included plasma histamine, IL-6, TNF-α levels, and PBMC biomarkers (H1R, NF-κB, TLR-4). RESULTS: Data from 20 patients in the intervention group and 22 patients in the control group were analyzed (patients in stages II and III were enrolled; no stage I cases were observed, and two stage IV patients [one per group] were excluded due to insufficient subgroup size). The intervention group showed a higher overall response rate (65%) than the control group (45.5%), though the difference was not statistically significant (p = 0.232). Stage III patients in the intervention group had a significantly higher response rate (90.91% [intervention] vs. 11.11% [control], p = 0.001). No adverse effects were reported. CONCLUSION: Desloratadine may improve treatment response in stage III breast cancer, supporting its potential role as a complementary agent in neoadjuvant chemotherapy. ETHICAL CODE: This study was registered with the Iranian Registry of Clinical Trials (IRCT) under the registration number IRCT20230221057485N1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LoratadineBreast NeoplasmsNeoadjuvant TherapyInflammationHistamine H1 Antagonists, Non-SedatingAntineoplastic Combined Chemotherapy ProtocolsHumansFemalePilot ProjectsMiddle AgedAdultNeoplasm StagingSingle-Blind MethodTreatment OutcomeTumor Necrosis Factor-alphaInterleukin-6AnthracyclinesHistamine

Stichwörter der Autor:innen

Breast cancerDesloratadineHistamineHistamine H1 antagonistNeoadjuvant chemotherapy

Substanzen

LoratadinedesloratadineHistamine H1 Antagonists, Non-SedatingTumor Necrosis Factor-alphaInterleukin-6AnthracyclinesHistamine

Autor:innen und Institutionen

  • Department of Immunology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
  • Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
  • Clinical Research Development Unit (CRDU), Agh-ghala Hospital, Golestan University of Medical Science, Gorgan, Iran.
  • Metabolic Disorders Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran.
  • Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
  • Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Electronic address: homdavoodi@yahoo.com.

Förderung

  • Golestan University of Medical Sciences

Zitieren

APA

Azimi, H., Jafari, A., Khandozi, S. R., Bagheri, Y., Saghaeian Jazi, M., Ghorbani, S., Roshandel, G., & Davoodi, H. (2026). Impact of Desloratadine on Treatment Response and Inflammation During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: A Randomized Pilot Study. Archives of Medical Research. https://doi.org/10.1016/j.arcmed.2025.103333

Vancouver

Azimi H, Jafari A, Khandozi SR, Bagheri Y, Saghaeian Jazi M, Ghorbani S, et al. Impact of Desloratadine on Treatment Response and Inflammation During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: A Randomized Pilot Study. Archives of Medical Research. 2026. doi:10.1016/j.arcmed.2025.103333

BibTeX
@article{Azimi2026,
  author = {Azimi, Hossein and Jafari, Afifeh and Khandozi, Seyed Reza and Bagheri, Yasser and Saghaeian Jazi, Marie and Ghorbani, Somayeh and Roshandel, Gholamreza and Davoodi, Homa},
  title = {Impact of Desloratadine on Treatment Response and Inflammation During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: A Randomized Pilot Study},
  journal = {Archives of Medical Research},
  year = {2026},
  doi = {10.1016/j.arcmed.2025.103333}
}
Kostenlos starten →